Latest Press Releases
May 16, 2022 • 8:00am EDT
Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results
-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive clinical data on VCN-01 and an upcoming oral presentation on VCN-11, a novel oncolytic adenovirus designed to evade neutralizing antibodies- - Reported positive safety data on SYN-020 intestinal alkaline phosphatase from the Phase 1 Multiple Ascending Dose clinical trial- -Formed Scientific Advisory Board and strengthened the leadership team to support transformative clinical development strategy and extension into oncology - -As of March 31, 2022, Synthetic Biologics reports $56.7 million in cash, which is expected to provide runway through the end of 2023- -Conference c...
Recent Press Releases
May 10, 2022 • 8:00am EDT
May 9, 2022 • 8:00am EDT
May 5, 2022 • 8:00am EDT
Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline